Physician profile
Jonathan E Abel
NPI 1700897196
$2,452.49
in general payments reported to CMS, 2019-2025
25 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.69 · 2022: $394 · 2023: $557 · 2024: $981 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $483.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $313.08 | 2023-2025 | |
| Lundbeck LLC | $199.21 | 2022-2024 | Rexulti, Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.15 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $140.82 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $125.39 | 2022-2023 | Ajovy, Austedo Xr, Austedo |
| Amgen INC. | $105.47 | 2024-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $95.67 | 2023-2024 | |
| Lilly USA, LLC | $90.88 | 2022-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $88.78 | 2022-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $88.66 | 2023-2025 | Keveyis |
| Abbvie INC. | $88.09 | 2023-2024 | Ubrelvy |
| Astellas Pharma US INC | $61.30 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $53.50 | 2022 | |
| Collegium Pharmaceutical, INC. | $43.48 | 2024-2025 | Belbuca |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $40.03 | 2024 | Xolair |
| Baxter Healthcare | $39.69 | 2022 | |
| Welch Allyn | $39.69 | 2021 | |
| Axsome Therapeutics, INC. | $30.67 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $27.63 | 2025 | Spravato |
| Alkermes, INC. | $26.95 | 2024 | Vivitrol |
| Neurocrine Biosciences, INC. | $20.45 | 2024 | Ingrezza |
| Aimmune Therapeutics, INC. | $19.84 | 2024 | |
| Cranial Technologies, INC | $16.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.99 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.